Summary of COVID-19 aviptadil studies

1. Youssef et al., The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

196 patient aviptadil late treatment RCT: 35% lower mortality (p=0.04) and 20% lower progression (p=0.27).
RCT 196 patients with critical COVID-19 respiratory failure showing improved survival but no significant difference in the primary endpoint of "alive and free of respiratory failure at day 60" with IV aviptadil.
Aug 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005660, https://c19p.org/youssef

2. Brown et al., Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

461 patient aviptadil late treatment RCT: 6% higher mortality (p=0.71) and 10% lower progression (p=0.54).
RCT 461 hospitalized patients with COVID-19-associated respiratory failure showing no significant difference in outcomes with aviptadil treatment.
Sep 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023001479, https://c19p.org/brown4

3. Gibbs et al., I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill Patients with COVID-19

118 patient aviptadil late treatment RCT: 79% worse recovery (p=0.02).
RCT 118 patients showing significantly worse recovery with aviptadil treatment.
Mar 2022, NCT04488081, https://www.prnewswire.com/news-releases/i-spy-covid-trial-sponsored-by-quantum-leap-healthcare-collaborative-suggests-no-clinical-benefit-with-addition-of-nebulized-zyesami-aviptadil-when-given-by-mouth-inhalation-in-critically-ill-patients-with-covid-19-301514508.html, https://c19p.org/gibbs